Cargando…
DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing
BACKGROUND: DuoBody®-CD3xCD20 (GEN3013) is a full-length human IgG1 bispecific antibody (bsAb) recognizing CD3 and CD20, generated by controlled Fab-arm exchange. Its Fc domain was silenced by introduction of mutations L234F L235E D265A. METHODS: T-cell activation and T-cell-mediated cytotoxicity we...
Autores principales: | Engelberts, Patrick J., Hiemstra, Ida H., de Jong, Bart, Schuurhuis, Danita H., Meesters, Joyce, Beltran Hernandez, Irati, Oostindie, Simone C., Neijssen, Joost, van den Brink, Edward N., Horbach, G. Jean, Verploegen, Sandra, Labrijn, Aran F., Salcedo, Theodora, Schuurman, Janine, Parren, Paul W.H.I, Breij, Esther C.W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992935/ https://www.ncbi.nlm.nih.gov/pubmed/31981978 http://dx.doi.org/10.1016/j.ebiom.2019.102625 |
Ejemplares similares
-
Mechanistic and pharmacodynamic studies of DuoBody-CD3x5T4 in preclinical tumor models
por: Kemper, Kristel, et al.
Publicado: (2022) -
DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity
por: Muik, Alexander, et al.
Publicado: (2022) -
Fab-arm exchange: What’s in a name?
por: Schuurman, Janine, et al.
Publicado: (2012) -
DuoHexaBody-CD37(®), a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies
por: Oostindie, Simone C., et al.
Publicado: (2020) -
Potent Preclinical Efficacy of DuoHexaBody-CD37 in B-Cell Malignancies
por: van der Horst, Hilma J., et al.
Publicado: (2020)